July 10, 2023
Eisai CEO Haruo Naito Eisai CEO Haruo Naito on July 7 expressed his excitement about the full US FDA approval granted to the company’s Alzheimer’s therapy Leqembi (lecanemab), vowing to expand patient access into other markets to achieve the drug’s...read more